InspireMD, Inc. (NSPR)

Market Cap	64.01M
Revenue (ttm)	6.57M
Net Income (ttm)	-25.52M
Shares Out	25.71M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,091
Open	2.600
Previous Close	2.500
Day's Range	2.481 - 2.600
52-Week Range	1.810 - 3.770
Beta	0.91
Analysts	Buy
Price Target	4.50 (+80.72%)
Earnings Date	Nov 4, 2024

About NSPR

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem le...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Employees: 66
• Stock Exchange: NASDAQ
• Ticker Symbol: NSPR
• Website: https://www.inspiremd.com

Financial Performance

In 2023, InspireMD's revenue was $6.21 million, an increase of 20.00% compared to the previous year's $5.17 million. Losses were -$19.92 million, 7.71% more than in 2022.

Analyst Forecast

According to one analyst, the rating for NSPR stock is "Buy" and the 12-month stock price forecast is $4.5.

Price Target

$4.5

(80.72% upside)

Analyst Consensus: Buy